证券记录 · 已归档季度
TEVA
Teva Pharmaceutical Industries Limited · Healthcare · Drug Manufacturers - Specialty & Generic
23被追踪持有人
0Δ持有人
176.53M持有股份
$3.56B报告持仓市值
+1新建仓位
−2清仓
动量输入（同类管理人）： 持有人广度 0.0% · 股份流向 -15.9% · 净新建仓位 -4.3% · 公式
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 151 | +7 | 369.28M | $12.48B | +9 | −1 |
| Q1 2026 | 146 | +3 | 327.68M | $9.78B | +10 | −8 |
| Q4 2025 | 144 | -1 | 326.44M | $10.18B | +3 | −3 |
| Q3 2025 | 23 | 0 | 176.53M | $3.56B | +1 | −2 |
| Q2 2025 | 21 | 0 | 197.53M | $3.31B | n/a | n/a |
| Q1 2025 | 18 | -3 | 84.56M | $1.30B | n/a | −3 |
| Q4 2024 | 21 | -1 | 89.79M | $1.98B | n/a | −1 |
| Q3 2024 | 21 | +2 | 78.93M | $1.23B | +2 | n/a |
| Q2 2024 | 19 | n/a | 61.88M | $1.01B | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 57.80M | +6.4% | $1.17B | 0.0% | ▲ Add | 2 | SEC ↗ ×20 |
| 2 | Fidelity (FMR) ✦ | 24.64M | -57.6% | $497.76M | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
| 3 | State Street Global Advisors ✦ (被动) | 17.15M | -0.8% | $346.44M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Glenview Capital ✦ | 16.69M | +5.5% | $337.19M | 8.2% | ▲ Add | 6 | SEC ↗ |
| 5 | Duquesne Family Office ✦ | 16.59M | +3.9% | $335.20M | 8.5% | ▲ Add | 5 | SEC ↗ |
| 6 | Geode Capital Management ✦ (被动) | 9.99M | +3.7% | $200.48M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Wellington Management ✦ | 6.90M | +39228.4% | $139.30M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 8 | Morgan Stanley ✦ | 6.48M | n/a | $130.80M | 0.0% | n/c | 1 | SEC ↗ ×13 |
| 9 | Goldman Sachs Group ✦ | 5.09M | n/a | $102.73M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 10 | Greenlight Capital (DME Capital) ✦ | 3.78M | 0.0% | $76.33M | 3.0% | Held | 6 | SEC ↗ ×2 |
| 11 | JPMorgan Chase ✦ | 2.77M | n/a | $55.96M | 0.0% | n/c | 1 | SEC ↗ ×24 |
| 12 | Viking Global Investors ✦ | 2.53M | -78.3% | $51.15M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 1.23M | -44.2% | $24.93M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | Millennium Management ✦ | 1.07M | -2.8% | $21.57M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 1.00M | -68.2% | $20.25M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | The Vanguard Group ✦ (被动) | 900.99K | +1.8% | $18.20M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 17 | Bridgewater Associates ✦ | 864.78K | 新增 | $17.47M | 0.1% | New | 1 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 508.70K | +10.3% | $10.28M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 19 | D. E. Shaw & Co. ✦ | 169.17K | +38.9% | $3.42M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 120.40K | -62.4% | $2.43M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | ARK Investment Management ✦ | 118.72K | -1.8% | $2.40M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 22 | GAMCO Investors ✦ | 89.20K | 0.0% | $1.80M | 0.0% | Held | 6 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 44.20K | +69.8% | $892,738 | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Bridgewater Associates | $17.47M | 0.1% |
已清仓
| Norges Bank | $31.25M | 曾为 0.0% |
| Adage Capital Partners | $8.95M | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 646 持有人, 666.61M 股份, $16.70B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Sep 18
Savage Brian
Officer · 2.52K 股 · $98,841
Sep 18
MIGNONE ROBERTO
Director · 367.60K 股 · $14.36M
Sep 18
Savage Brian
Officer · 4.50K 股 · $174,221
Sep 18
Savage Brian
Officer · 314 股 · $12,153
Aug 21
Weiss Amir
Officer · 2.50K 股 · $94,077
Aug 21
Satchi-Fainaro Ronit
Director · 415 股 · $15,459
Aug 21
Weiss Amir
Officer · 6.95K 股 · $261,224
Aug 17
Lippman Evan
Officer · 18.60K 股 · $680,291
Aug 05
Zaks Tal Zvi
Director · 17 股 · $593
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据